CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL FIRST AMENDMENT TO STRATEGIC COLLABORATION...Strategic Collaboration and License • May 13th, 2022 • EQRx, Inc. • Pharmaceutical preparations • New York
AGREEMENT (“First Amendment”) effective as of December 14, 2021 (“First Amendment Effective Date”) by and among HANSOH (SHANGHAI) HEALTHTECH CO., LTD., a corporation incorporated under the laws of China having its principal place of business at Room 101, No.287 Xiangke Road and No.1158 Haike Road, China (Shanghai) Pilot Free Trade Zone, China (“Hansoh Healthtech”) and JIANGSU HANSOH PHARMACEUTICAL GROUP COMPANY LTD., a corporation incorporated under the laws of China having its principal place of business at No. 9 Dongjin Road, Huaguoshan Avenue, Lianyuangang, Jiangsu, China (“Jiangsu Hansoh” and together with Hansoh Healthtech, “Hansoh”), and EQRX, INC., a Delaware corporation having its principal place of business at 50 Hampshire St., Cambridge, MA 02139, United States (“EQRx”). Hansoh and EQRx are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
FIRST AMENDMENT TO SUBLEASE AGREEMENTSublease Agreement • May 13th, 2022 • EQRx, Inc. • Pharmaceutical preparations
made as of July 9, 2020, by and between Surface Oncology, Inc., a Delaware corporation (“Sublessor”), and EQRx, INC., a Delaware Corporation (“Sublessee”).
SECOND AMENDMENT TO SUBLEASE AGREEMENTSublease Agreement • May 13th, 2022 • EQRx, Inc. • Pharmaceutical preparations
THIS SECOND AMENDMENT TO SUBLEASE AGREEMENT (this “Amendment”) is made as of May 11, 2022, by and between Surface Oncology, Inc., a Delaware corporation (“Sublessor”), and EQRx International, Inc. (formerly known as EQRx, Inc.), a Delaware Corporation (“Sublessee”).
